High-throughput peptide screening is a powerful approach for discovering biologically active peptides. However, false positives—peptides that appear active in screening assays but fail to demonstrate true target engagement—can slow down development and increase costs.

Precision medicine aims to tailor therapies to individual patients based on their genetic, proteomic, and molecular profiles.

The development of biologics—therapeutics derived from peptides, proteins, or antibodies—has transformed modern medicine. Among these, peptides have emerged as highly versatile molecules capable of modulating complex biological targets with precision.

Peptides offer unique advantages in cancer research, including high specificity, structural adaptability, and the ability to target protein–protein interactions often inaccessible to small molecules.

Peptide therapeutics have emerged as a powerful solution for targets that are challenging for small molecules or biologics, such as protein–protein interactions (PPIs), allosteric sites, or highly dynamic proteins. Central to this capability is the use of 3D-structured peptide libraries

High-throughput peptide screening has become an essential strategy in modern drug discovery, enabling researchers to identify biologically active peptides rapidly from libraries containing trillions of variants. Understanding the workflow—from diverse peptide library design to lead selection

In peptide drug discovery, peptide structure has a profound impact on screening outcomes. Libraries that include linear, cyclic, and bicyclic peptides allow researchers to explore a wide range of conformations, increasing the likelihood of identifying potent hits.